Oral liraglutide nanomicelle achieves 5x higher bioavailability with superior metabolic benefits over injection | Research

The takeaway

Oral liraglutide nanomicelle (LDD-NM) achieved 4.63-fold higher bioavailability than unformulated oral liraglutide, and 12-week oral treatment produced superior effects on insulin resistance, brown fat activation, and lipid metabolism versus subcutaneous injection.

Oral > injection for metabolism
Oral liraglutide nanomicelle not only achieved higher bioavailability but produced superior metabolic effects versus subcutaneous injection—suggesting oral route engages different pathways

What the researchers found

LDD-NM: 75.9 nm particles; permeability +1347%; oral bioavailability 5.14% vs 1.11% (4.63x). 12-week oral: superior to SC for HOMA-IR, HbA1c, BAT activation, anti-inflammatory genes, lipid metabolism. Absorption: clathrin endocytosis + macropinocytosis + ASBT pathway.

Why it matters

Oral GLP-1 delivery is the holy grail of peptide drug development. This formulation not only achieves meaningful oral bioavailability but shows the oral route may produce different (potentially superior) metabolic effects than injection.

How the study worked

Nanomicelle synthesis (electrostatic complexation + DDM surfactant). Caco-2/HT29-MTX-E12 permeability. Rat oral bioavailability. 12-week oral treatment in diabetic rats. Metabolic, adipose tissue, and gene expression analysis.

What this study cannot tell us

Rat study. Oral bioavailability still low (5.14%). Daily dosing of 20 mg/kg is high. Manufacturing scalability unclear. Human translation needed.

How to read the evidence

Comprehensive preclinical formulation study with bioavailability, mechanism, and 12-week efficacy data. Strong proof of concept.

When this study was published

Published in 2025.

The bigger picture

The finding that oral delivery produces superior metabolic effects versus subcutaneous injection is unexpected and paradigm-shifting. It suggests oral GLP-1 may engage different gut-liver-fat axis pathways than injected forms.

Questions still open

Why does oral liraglutide show superior metabolic effects versus injection?
Can the nanomicelle bioavailability be improved further?
Would this formulation work for other peptide drugs (insulin, semaglutide)?

Common questions

Could liraglutide become an oral pill?

This study developed a nanomicelle formulation that increases oral absorption of liraglutide nearly 5-fold. Remarkably, oral delivery produced even better metabolic results than injections in a 12-week rat study. If translated to humans, this could make daily liraglutide pills a reality.

How does the nanomicelle work?

The formulation wraps liraglutide in tiny bile acid-surfactant micelles (75.9 nm). These protect the peptide from digestive destruction and help it cross the intestinal wall through multiple absorption pathways (endocytosis, macropinocytosis, and bile acid transporters). This dramatically increases how much drug reaches the bloodstream.

Read the original research

An oral liraglutide nanomicelle formulation conferring reduced insulin-resistance and long-term hypoglycemic and lipid metabolic benefits.

Journal of controlled release : official journal of the Controlled Release Society, 378, 637-655

View on PubMed ↗Publisher’s paper ↗

Citation

Subedi, Laxman; Bamjan, Arjun Dhwoj; Phuyal, Susmita; Shim, Jung-Hyun; Cho, Seung-Sik; Seo, Jong Bae; Chang, Kwan-Young; Byun, Youngro; Kweon, Seho; Park, Jin Woo. (2025). An oral liraglutide nanomicelle formulation conferring reduced insulin-resistance and long-term hypoglycemic and lipid metabolic benefits.. Journal of controlled release : official journal of the Controlled Release Society, 378, 637-655. https://doi.org/10.1016/j.jconrel.2024.12.039